Thirty years' on surgery and related basic research of hepatocellular carcinoma

Annals of the College of Surgeons of Hong Kong

Volumn 7, Issue 1, 2003, Pages 11-17

  Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Basic research; Hepatocellular carcinoma; Innovation; Prognosis; Surgery

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; BATIMASTAT; CANCER ANTIBODY; CAPECITABINE; DIFFERENTIATION INDUCING FACTOR; DOXIFLURIDINE; FERRITIN ANTIBODY I 131; FLUOROURACIL; HEPARIN; IODINATED POPPYSEED OIL;

ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE MODEL; DRUG METABOLISM; EARLY DIAGNOSIS; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER LOBECTOMY; LIVER RESECTION; METASTASIS; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PREDICTION; REVIEW; SMALL CELL CARCINOMA; TUMOR VASCULARIZATION;

EID: 0038207931     PISSN: 10284001     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2034.2003.00154.x     Document Type: Review

References (57)

1. Pisani P, Parkin M, Bray F, Ferlay J. Estimates of the worldwide moratlity from 25 cancers in 1990. Int J. Cancer 1999; 83: 18-29.
2. Jemal A, Thomas A, Murray T, Thum M. Cancer statistics, 2002. CA Cancer J. Clin. 2002; 52: 23-47.
3. Jin F, Xiang YB, Gao YT. Cancer survival in Shanghai, People's Republic of China. In: Sankaranaryanan R, Black RJ, Parkin DM (eds). Cancer Survival in Developing Countries. IARC Scientific Publications No. 145. International Agency for Research on Cancer, Lyon, 1998; 37-50.
4. Abelev GI. Alpha fetoprotein in ontogenesis and its association with malignant tumors. Adv. Cancer Res. 1971; 14: 295-358.
5. Tang ZY, Yu YQ, Lin ZY et al. Diagnosis, treatment and prognosis of small hepatocellular carcinoma - analysis of 30 cases. Zhonghua Yixue Zazhi (Natl Med. J. China) 1978; 58: 608-10 (in Chinese with English abstract).
6. Tang ZY, Yu YQ, Lin ZY et al. Small hepatocellular carcinoma - clinical analysis of 30 cases. Chin Med. J. 1979; 59: 35-40.
7. Tang ZY, Yang BH. Early detection of subclinical hepatocellular carcinoma. In: Tang ZY (ed). Subclinical Hepatocellular Carcinoma. Springer, Berlin, 1985; 12-21.
8. Tang ZY, Yang BH. New concepts of diagnosis of subclinical hepatocellular carcinoma. In: Tang ZY (ed). Subclinical Hepatocellular Carcinoma. Springer, Berlin, 1985; 22-35.
9. Tang ZY. Surgical treatment of subclinical hepatocellular carcinoma. In: Tang ZY (ed). Subclinical Hepatocellular Carcinoma. Springer, Berlin, 1985; 63-77.
10. Tang ZY. Surgical treatment of subclinical cases of hepatocellular carcinoma. In: Okuda K, Ishak KG (eds). Neoplasms of the Liver. Springer, Tokyo, 1987; 367-73.
11. Tang ZY, Yu YQ, Zhou XD et al. Surgery of small hepatocellular carcinoma - analysis of 144 cases. Cancer 1989; 64: 536-41.
12. Tang ZY, Yu YQ, Zhou XD. Surgical resection of small hepatocellular carcinoma. In: Wanebo HJ (ed). Surgery for Gastrointestinal Cancer - a Multidisciplinary Approach. Lippincott-Raven, Philadelphia, 1997, 503-12.
13. Tang ZY, Yu YQ, Zhou XD. An important approach to prolonging survival further after radical resection of AFP positive hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 1984; 3: 359-66.
14. Tang ZY, Ying YY, Gu TJ. Hepatocellular carcinoma: changing concepts in recent years. In: Popper H, Schaffner F (eds). Progress in Liver Diseases, Vol. VII. Grune & Stratton, New York, 1982; 637-47.
15. Tang ZY, Ma ZC, Xue Q et al. Transplantation of human hepatocellular carcinoma in nude mice. I. Establishent of model and its serological and morphological features. Shanghai Yikedaxue Xuebao (Acta Acad. Med. Primae Shanghai) 1982; 9: 21-6 (in Chinese with English abstract).
16. Tang ZY, Ma ZC. Establishment of transplantable human hepatocellular carcinoma in nude mice and their use in studies of tumor markers and radioimmunodetection. In: Tang ZY, Wu MC, Xia SS (eds). Primary Liver Cancer. Springer-Verlag, Berlin, 1989; 172-9.
17. Bao YM, Tang ZY, Ma ZC et al. Radiotherapy alternated with chemotherapy and immunotherapy on nude mice bearing human hepatocellular carcinoma. Zhonghua Zhongliu Zazhi (Chin J. Oncol.) 1988; 10: 382-4 (in Chinese with English abstract).
18. Bao YM, Tang ZY, Liu KD, Ma ZC, Xie Q, Qin WL. Radioimmunotherapy combined with chemotherapy and immunotherapy for nude mice bearing human hepatoellular carcinoma. Zhonghua Zhongliu Zazhi (Chin J. Oncol.) 1989; 11: 245-7 (in Chinese with English abstract).
19. Tang ZY, Liu KD, Fan Z et al. A decade's studies on the immunotargeting therapy of hepatocellular carcinoma. Antibody Immunoconj. Radiophar. 1993; 6: 155-65.
20. Liu KD, Tang ZY, Bao YM et al. Radiommunotherapy for hepatocellular carcinoma (HCC) using 131 anti HCC isoferritin IgG: Preliminary results of experimental and clinical studies. Int. J. Radiat. Oncol. Biol. Phys. 1989; 16: 319-23.
21. Zeng ZC, Tang ZY, Xie H et al. Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb: Preliminary results. J. Cancer Res. Clin. Oncol. 1993; 119: 257-9.
22. Lu JZ, Tang ZY, Liu KD et al. Hepatic artery injection of I-131 (or I-125) labeled lipid contrast medium: Preliminary observation of therapeutic use in patients with primary liver cancer. Zhonghua Heyixue Zazhi (Chin J. Nucl. Med.) 1991; 11: 93-5 (in Chinese with English abstract).
23. Tang ZY, Liu KD, Bao YM et al. Radioimmunotherapy in the multimodality treatment of hepatocellular carcinoma with reference to second-look resection. Cancer 1990; 65: 211-15.
24. Tang ZY, Yu YQ, Zhou XD et al. Cytoreduction and sequential resection: A hope for unresectable primary liver cancer. J. Surg. Oncol. 1991; 47: 27-31.
25. Tang ZY, Yu YQ, Zhou XD et al. Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma - evaluation with analysis of 72 patients. World J. Surg. 1995; 19: 784-9.
26. Tang ZY. Treatment of unresectable hepatocellular carcinoma: cytoreduction by chemotherapy, hepatic artery ligation, radioimmunotherapy, and other methods. In: Okuda K, Tabor E (eds). Liver Cancer. Churchill Livingstone, New York, 1997; 537-41.
27. Tang ZY, Zhou XD, Lin ZY et al. Surgical treatment of hepatocellular carcinoma and related basic research with special reference to recurrence and metastasis. Chin. Med. J. 1999; 112: 887-91.
28. Tang ZY. Surgery of hepatocellular carcinoma with special reference to studies on metastasis and recurrence. Gastroenterol. Today 2000; 4: 191-5.
29. Zhou XD, Yu YQ, Tang ZY et al. Surgical treatment of recurrent hepatocellular carcinoma. Hepato-Gastroenterol. 1993; 40: 333-6.
30. Tang ZY. Small hepatocellular carcinoma. In: Tang ZY, Wu WC, Xia SS (eds). Primary Liver Cancer. Springer, Berlin, 1989; 191-203.
31. Liang XH, Loncarevic IF, Tang ZY et al. Resection of hepatocellular carcinoma: Oligocentric origin of recurrent and multinodular tumours. J. Gastroenterol. Hepatol. 1991; 6: 77-80.
32. He B, Tang ZY, Liu KD, Zhou G. Analysis of the cellular origin of hepatocellular carcinoma by p53 genotype. J. Cancer Res. Clin. Oncol. 1996; 122: 763-6.
33. Sun FX, Tang ZY, Liu KD et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int. J. Cancer 1996; 66: 239-43.
34. Sun HC, Li XM, Xue Q et al. Study of angiogenesis induced by metastatic and non-metastatic liver cancer by corneal micropocket model in nude mice. World J. Gastroenterol. 1999; 5: 116-8.
35. Tian J, Tang ZY, Ye SL et al. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expression of the factors associated with metastasis. Br. J. Cancer 1999; 81: 814-21.
36. Li Y, Tang ZY, Ye SL et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J. Gastroenterol. 2001; 7: 630-6.
37. Qin LX, Tang ZY, Liu KD et al. p53 mutations may be related to tumor invasiveness of human hepatocellular carcinoma in China. Oncol. Rep. 1995; 2: 1175-9.
38. Qin LX, Tang ZY, Liu KD et al. Alterations of CDKN2 (P16/ MTS1) exon 2 in human hepatocellular carcinoma. Oncol. Rep. 1996; 3: 405-8.
39. Qiu SJ, Ye SL, Wu ZQ et al. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 1998; 124: 253-8.
40. Wang XM, Tang ZY, Xue Q et al. Transforming growth factor α induces proliferation and expression of epidermal growth factor receptor in hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res. 1995; 14: 179-84.
41. Yao M, Zhou XD, Zha XL et al. Expression of the integrin α5 subunit and its mediated cell adhesion in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 1997; 123: 435-40.
42. Sun JJ, Zhou XD, Liu YK et al. Invasion and metastasis of liver cancer: expression of intercellular adhesion molecule 1. J. Cancer Res. Clin. Oncol. 1999; 125: 28-34.
43. Zheng Q, Tang ZY, Xue Q et al. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J. Cancer Res. Clin. Oncol. 2000; 126: 641-6.
44. Zheng XY, Lin ZY, Tang ZY et al. The abundance of NM23-H1 mRNA is related with in situ microenvironment and intrahepatic metastasis in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 1998; 17: 337-41.
45. Sun HC, Tang ZY, Zhou G, Li XM. Kai-1 gene expression in hepatocellular carcinoma and its relationship with intrahepatic metastases. J. Exp. Clin. Cancer Res. 1998; 17: 307-11.
46. Tang ZY, Qin LX, Wang XM et al. Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin. Med. J. 1998; 111: 313-18.
47. Qin LX, Tang ZY, Sham JST et al. The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res. 1999; 59: 5662-5.
48. Qin LX, Tang ZY, Ye SL et al. Chromosome 8p deletion is associated with metastasis of human hepatocellular carcinoma when high and low metastatic models are compared. J. Cancer Res. Clin. Oncol. 2001; 127: 482-8.
49. Li XM, Tang ZY, Qin LX et al. Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellula rcarcinoma. J. Exp. Clin. Cancer Res. 1999; 18: 511-17.
50. Zhou J, Tang ZY, Fan J et al. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J. Cancer Res. Clin. Oncol. 2000; 126: 57-61.
51. Li XM, Tang ZY, Zhou G et al. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 1998; 17: 13-7.
52. Qin LX, Tang ZY, Li XM et al. Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma. Ann. Acad. Med. Singapore 1999; 28: 147-51.
53. Xia JL, Yang BH, Tang ZY et al. Inhibitory effect of the angiogenesis inhibitor TNP-470 on tumor growth and metastasis in nude mice bearing human hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 1997; 123: 383-7.
54. Wang L, Tang ZY, Qin LX et al. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000; 32: 43-8.
55. Liao Y, Tang ZY, Ye SL et al. Modulation of apoptosis, tumorigenesity and metastatic potential with antisense H-ras oligodeoxynucleotides in a high metastatic tumor model of hepatoma: LCI-D20. Hepato-GastroenteroL 2000; 47: 365-70.
56. Bu W, Tang ZY, Sun FX et al. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepato-Gastroenterol. 1998; 45: 1056-61.
57. Sun JJ, Zhou XD, Liu YK et al. Inhibitory effects of synthetic β peptide on invasion and metastasis of liver cancer. J. Cancer Res. Clin. Oncol. 2000; 126: 595-600.